Trial Details

COMPLETED
Basic Information
Clinical ID c497
Identifier NCT06528665
Trial Title Determine PK Profiles of Ozanimod and Its' Major Metabolites in Healthy Subjects
Trial URL Visit Original Page
Study Information
Study Results

NO

Conditions Multiple Sclerosis|Ulcerative Colitis
Interventions DRUG: ZEPOSIA® indicated for the treatment of: Relapsing forms of multiple sclerosis, and active ulcerative colitis in adults
Participant Information
Sponsor Corium Innovations, Inc.
City Selangor
Country/Region Malaysia
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT
Study Design
Study Type OBSERVATIONAL
Phase NULL
Time Information
Start Date 2025-02-10
Primary Completion Date 2025-03-16
Completion Date 2025-04-16